Author:
Rossignol Patrick,David Lea,Chan Christine,Conrad Ansgar,Weir Matthew R.
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Veltassa® (patiromer) for oral suspension [package insert]. Redwood City, CA: Relypsa, Inc. 2018. https://www.veltassa.com/pi.pdf.
2. European Medicines Agency. Veltassa (patiromer). https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa. Updated 19 June 2019. Accessed 1 July 2020.
3. Rossignol P. A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology. Eur Heart J Suppl. 2019;21(Suppl A):A48-54. https://doi.org/10.1093/eurheartj/suy032 (Erratum in: JAMA Intern Med. 2020;180(4):618).
4. Noel JA, Bota SE, Petrcich W, Garg AX, Carrero JJ, Harel Z, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025–33. https://doi.org/10.1001/jamainternmed.2019.0631.
5. Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020;35(9):1518–26. https://doi.org/10.1093/ndt/gfz150.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献